---
title: TEAM-NB 立场文件
---

# TEAM-NB 立场文件

**TEAM-NB**（公告机构团队）是欧洲医疗器械公告机构协会，其立场文件从公告机构角度提供 MDR/IVDR 实施的协调化指导。

::: tip 来源
[TEAM-NB 文件页面](https://www.team-nb.org/team-nb-documents/) · [立场文件清单 (PDF)](https://www.team-nb.org/wp-content/uploads/2026/02/Team-NB-List-PositionPapers-20260216.pdf)
:::

## 立场文件

| 文件 | 日期 |
|------|------|
| [联合使用试剂器械与其他设备的安全性与性能论证](https://www.team-nb.org/wp-content/uploads/2026/02/Team-NB-PositionPaper-Demonstration-of-Safety-and-Performance-for-Combinatorial-Use-of-Devices-or-Equipment-V1-20260216.pdf) | 2026-02 |
| [附件 VII](https://www.team-nb.org/wp-content/uploads/2025/12/Team-NB-PositionPaper-Annex-VII-V1-20251216.pdf) | 2025-12 |
| [IVD SARS-CoV-2 降级分类](https://www.team-nb.org/wp-content/uploads/2025/12/Team-NB-PositionPaper-IVD-SARS-CoV-2-down-classification-V1-20251212.pdf) | 2025-12 |
| [MDR 申请与适当监督 -- 转让协议](https://www.team-nb.org/wp-content/uploads/2025/11/Team-NB-PositionPaper-MDR-Application-and-appropriate-surveillance-Transfer-agreement-V1-20251022.pdf) | 2025-10 |
| [IVDR 重大变更 V2](https://www.team-nb.org/wp-content/uploads/2025/10/Team-NB-PositionPaper-IVDR-Significant-changes-V2.pdf) | 2025-10 |
| [最佳实践指南 -- IVDR V2](https://www.team-nb.org/wp-content/uploads/2025/09/Team-NB-PositionPaper-BPG-IVDR-V2-20250903.pdf) | 2025-09 |
| [孤儿 IVDR 医疗器械](https://www.team-nb.org/wp-content/uploads/2025/07/Team-NB-PositionPaper-Ophan-IVDR-Medical-Devices-V1-20250717.pdf) | 2025-07 |
| [IVDR 下的软件认定 V2](https://www.team-nb.org/wp-content/uploads/2025/06/Team-NB-PositionPaper-Software-Qualification-under-the-IVDR-V2-20250627.pdf) | 2025-06 |
| [IVDR 认证流程共识文件](https://www.team-nb.org/wp-content/uploads/2025/04/Team-NB-PositionPaper-IVDR-Certification-Process-Consensus-Document-V1-20250409.pdf) | 2025-04 |
| [EU AI Act V2](https://www.team-nb.org/wp-content/uploads/2025/04/Team-NB-PositionPaper-EU-AI-Act-V2-20250409.pdf) | 2025-04 |
| [最佳实践指南 -- EU MDR 技术文档 V3](https://www.team-nb.org/wp-content/uploads/2025/04/Team-NB-PositionPaper-BPG-TechnicalDocEU-MDR-2017-745-V3-20250409.pdf) | 2025-04 |
| [MDR 认证流程共识文件](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-MDR-Certification-Process-Consensus-Document-20241218.pdf) | 2024-12 |
| [Team-NB / IG-NB 联合 -- AI 医疗器械问卷 V1.1](https://www.team-nb.org/wp-content/uploads/2025/02/Joint-Team-NB-IG-NB-PositionPaper-AI-in-MD-Questionnaire-V1-20241125.pdf) | 2024-12 |
| [IVD 转让协议](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-IVD-Transfer-Agreement-20240911.pdf) | 2024-09 |
| [转让协议 V2（含说明）](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-TransferAgreement-v02-20240702-with-instructions.pdf) | 2024-07 |
| [医疗器械生命周期](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-Lifetime-Medical-Device-20231127.pdf) | 2023-11 |
| [遗留器械监督转让协议 V1](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-TransferAgreement-V1-20230811-1.pdf) | 2023-08 |
| [MDR 过渡时间线 -- 公告机构产能 V1](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-MDRTransitionTimelines-NotifiedBodyCapacity-V1-20230810.pdf) | 2023-08 |
| [公告机构确认函 EU 2023/607 V2](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-NB-ConfirmationLetterEU2023-607-20230503-V2.pdf) | 2023-07 |
| [混合审核 V2](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-HybridAudits-V2-20230516.docx) | 2023-05 |
| [MDCG 2022-14 第17项 -- 附条件证书](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-Certificates_under_conditions-V1-20221128.docx) | 2022-11 |
| [自愿转让协议 V1](https://www.team-nb.org/wp-content/uploads/2025/01/Team-NB-PositionPaper-VoluntaryTransfer-Agreement-V1-20221005.pdf) | 2022-10 |
| [网络安全 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-CyberSecurity-V1-20221005.pdf) | 2022-10 |
| [超适应症使用 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-Off-LabelUse-V1-20221005.pdf) | 2022-10 |
| [符合性评估 -- 多重检测 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-ConfAssessment-Multiplexassays-V1-20220714.pdf) | 2022-07 |
| [抽样方案修改 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-ModificationsSamplingPlan-V1-20220128.pdf) | 2022-01 |
| [MDR/IVDR 实施 V3](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-on-MDR_IVDR-Implementation-V3-20211201.pdf) | 2021-12 |
| [第117条 -- 公告机构意见模板 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-Article117-NB-Opinion-Template-V120211006.pdf) | 2021-10 |
| [人工智能 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-Artificial-Intelligence-V1-20211006.pdf) | 2021-10 |
| [植入物卡](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-ImplantCard-20210720.pdf) | 2021-07 |
| [D类符合性评估 V4.4](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-ClassD-conformity-assessment-V4.4-20210519.pdf) | 2021-05 |
| [第117条 -- 药械组合产品重大变更](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-Art117-Substantial-Changes-DrugDeviceCombination-20211221.pdf) | 2020-12 |
| [远程审核 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-RemoteAudits-V1-20201118.pdf) | 2020-11 |
| [技术合规流程 (TCP) V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-TCP-V1-20200722.pdf) | 2020-07 |
| [第117条文档要求 V1](https://www.team-nb.org/wp-content/uploads/2026/01/Team-NB-PositionPaper-Documentation-Requirements-Article117-V1-20200401.pdf) | 2020-04 |
